We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





MeMed Displays Disruptive Technology Award Finalist COVID-19 Severity Test at AACC 2021

By LabMedica International staff writers
Posted on 29 Sep 2021

MeMed (Haifa, Israel) displayed the MeMed COVID-19 Severity Test, the Disruptive Technology Award finalist, at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, the largest global scientific conference & tradeshow in the field of laboratory medicine. More...

MeMed was named a finalist for the American Association of Clinical Chemistry’s (AACC) Disruptive Technology Award for the MeMed COVID-19 Severity test, which stratifies the risk that a patient with COVID-19 will experience severe outcomes. It reads the immune-system in real time to accurately determine whether SARS-CoV-2 patients are likely to have a severe outcome.

MeMed COVID-19 Severity is a pioneering host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 will experience severe outcomes. The test runs in 15 minutes on the company’s cutting edge multi-purpose platform, MeMed Key, for quantitative diagnostic immunoassays that opens the way to central lab performance at the point-of-need, using chemiluminescence detection technology. MeMed Key provides accuracy similar to large central lab immunoassay platforms in a miniaturized and point-of-need format. It has a wide dynamic range from single pg/ml to µg/ml, which opens the way to measuring host and pathogen based immunoassays that are currently only measurable at the central lab.

Also on display at the event was MeMed BV, a host-immune response assay that can aid to distinguish between bacterial and viral infections delivering results in 15 minutes from serum. MeMed BV computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response/co-infection versus a viral immune response. Run on the compact MeMed Key, it is the only test for distinguishing bacterial from viral infections that has been validated in multinational, double-blind and external clinical studies.

Related Links:
MeMed 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.